Loading clinical trials...

COMPLETEDPhase 1NCT02808416

Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

Cancer patients with brain metastases (BM) have poor prognosis. Current treatments produce limited efficacy. Recent advance in cancer immunotherapy has provided important new means to treat cancer pat...

Lead sponsor: Guangdong 999 Brain Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

NCT02800486 · Glioblastoma, Anaplastic Astrocytoma, and more

RECRUITINGPhase 2

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

NCT05419518 · Neoplasm Metastases, Metastases, Neoplasm

RECRUITINGPhase 2

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

NCT02691923 · Brain Cancer

RECRUITINGPhase 1/2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

NCT03213002 · Glioblastoma Multiforme (GBM), Glioblastoma, and more

RECRUITINGPhase 1/2

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898 · Glioblastoma, Brain Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 27, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment10

Start dateMar 2016

Last updatedMay 27, 2022

Condition

Brain Cancer Neoplasm Metastases

Locations shown

Guangdong 999 Brain Hospital

Guangzhou, Guangdong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 27, 2022Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

Trial snapshot

Condition

Locations shown

For caregivers